Loading candles…
Advanced Enzyme Technologies Limited is a company engaged in the research, development, commercial-scale manufacturing, and global marketing of enzyme and probiotic products. Operating within the enzymes, probiotics, human nutrition, animal nutrition, and industrial bio-processing industries, it offers over 400 proprietary products developed from more than 68 enzymes and probiotics. The company serves over 700 customers across more than 45 countries. It is recognized as the largest enzyme company in India and is the second-largest integrated enzyme player listed globally. Advanced Enzyme Technologies Limited is publicly traded, although no information about its founders, key management, or headquarters is provided.
This page is a live market overview for ADVANCED ENZYME TECH LTD (ADVENZYMES) on the NSE. As a listed security, ADVANCED ENZYME TECH LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for ADVENZYMES before placing trades on tick2trade.
As of the latest feed, ADVENZYMES last traded at ₹324.35 on NSE, down ₹5.45 (1.65%) from the previous close of ₹329.8. Today's session range is ₹322 – ₹332, against a 52-week band of ₹251.95 – ₹419. Traded volume today stands at 1.78L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for ADVENZYMES in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether ADVENZYMES is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for ADVANCED ENZYME TECH LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in ADVENZYMES. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated ADVENZYMES option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Buyback | To consider buyback for equity shares | 8 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 8 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 9 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 31 Jan 2026 |
| Unaudited Results - Q2 & FY25 | This is to inform that the Meeting of Board of Directors of the Company is scheduled to be held on Wednesday, November 12, 2025, inter alia, to consider and … | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 2 Aug 2025 |
| Intimation | Intimation of Board Meeting, Record date for interim dividend, if declared by the Board andclosure of Trading Window | 13 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.